Pages that link to "Q38308285"
Jump to navigation
Jump to search
The following pages link to A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence (Q38308285):
Displaying 50 items.
- Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen (Q24632895) (← links)
- Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc (Q24653031) (← links)
- Repression of E2F1-mediated transcription by the ErbB3 binding protein Ebp1 involves histone deacetylases (Q24680884) (← links)
- Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers (Q28069910) (← links)
- p21-activated Kinase-1 Signaling Mediates Cyclin D1 Expression in Mammary Epithelial and Cancer Cells (Q28207743) (← links)
- Autocrine human growth hormone inhibits placental transforming growth factor-beta gene transcription to prevent apoptosis and allow cell cycle progression of human mammary carcinoma cells (Q28216713) (← links)
- Evaluation of cell cycle arrest in estrogen responsive MCF-7 breast cancer cells: pitfalls of the MTS assay (Q28478434) (← links)
- Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer (Q30419997) (← links)
- Pathways to tamoxifen resistance (Q30441001) (← links)
- Asf1b, the necessary Asf1 isoform for proliferation, is predictive of outcome in breast cancer (Q33292388) (← links)
- Sex differences in estrogen receptor subcellular location and activity in lung adenocarcinoma cells (Q33695898) (← links)
- Cyr61, a member of CCN family, is a tumor suppressor in non-small cell lung cancer (Q34094902) (← links)
- Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways (Q34147910) (← links)
- Estrogens and cell-cycle regulation in breast cancer (Q34336956) (← links)
- BRG1/BRM and prohibitin are required for growth suppression by estrogen antagonists (Q34348559) (← links)
- p14ARF post-transcriptional regulation of nuclear cyclin D1 in MCF-7 breast cancer cells: discrimination between a good and bad prognosis? (Q34364725) (← links)
- Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer (Q34394399) (← links)
- FOXA1 is a key determinant of estrogen receptor function and endocrine response (Q34508204) (← links)
- E2F4 regulatory program predicts patient survival prognosis in breast cancer (Q35000629) (← links)
- The role of prolactin in mammary carcinoma (Q35067253) (← links)
- The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer (Q35191588) (← links)
- Mediator subunits MED1 and MED24 cooperatively contribute to pubertal mammary gland development and growth of breast carcinoma cells (Q35867938) (← links)
- Heterochromatin protein 1alpha: a hallmark of cell proliferation relevant to clinical oncology (Q36042059) (← links)
- Androgen receptor as a targeted therapy for breast cancer. (Q36135807) (← links)
- Estrogens and progesterone promote persistent CCND1 gene activation during G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cycli (Q36700634) (← links)
- PET Radiotracers for Imaging the Proliferative Status of Solid Tumors (Q37401153) (← links)
- Biological determinants of endocrine resistance in breast cancer (Q37585095) (← links)
- Progress with palbociclib in breast cancer: latest evidence and clinical considerations (Q37632170) (← links)
- A low abundance pool of nascent p21WAF1/Cip1 is targeted by estrogen to activate cyclin E*Cdk2. (Q38296317) (← links)
- Characterization of the condensin component Cnap1 and protein kinase Melk as novel E2F target genes down-regulated by 1,25-dihydroxyvitamin D3. (Q38321368) (← links)
- Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A. (Q38326758) (← links)
- CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update (Q38870640) (← links)
- c-Myc suppresses p21WAF1/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells. (Q40448475) (← links)
- Regulation of cyclin expression and cell cycle progression in breast epithelial cells by the helix-loop-helix protein Id1. (Q40503186) (← links)
- Cyr61 suppresses the growth of non-small-cell lung cancer cells via the beta-catenin-c-myc-p53 pathway (Q40568061) (← links)
- The cyclin-dependent kinase inhibitor p21WAF1/Cip1 is an antiestrogen-regulated inhibitor of Cdk4 in human breast cancer cells (Q40763839) (← links)
- Overexpression of cyclin E in Mongolian gerbil with Helicobacter pylori-induced gastric precancerosis (Q42257574) (← links)
- Insulin/insulin-like growth factor-I and estrogen cooperate to stimulate cyclin E-Cdk2 activation and cell Cycle progression in MCF-7 breast cancer cells through differential regulation of cyclin E and p21(WAF1/Cip1). (Q43597891) (← links)
- Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression (Q43709177) (← links)
- Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells (Q43723448) (← links)
- Cyclin D1 overexpression induces progestin resistance in T-47D breast cancer cells despite p27(Kip1) association with cyclin E-Cdk2. (Q43759022) (← links)
- Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest (Q44049464) (← links)
- Removal of Cdk inhibitors through both sequestration and downregulation in zearalenone-treated MCF-7 breast cancer cells (Q44060332) (← links)
- Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells (Q44224229) (← links)
- Estrogens down-regulate p27Kip1 in breast cancer cells through Skp2 and through nuclear export mediated by the ERK pathway (Q44540468) (← links)
- Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer (Q50333196) (← links)
- Lycopene inhibition of IGF-induced cancer cell growth depends on the level of cyclin D1. (Q51240694) (← links)
- ERα-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer. (Q55426345) (← links)
- Estrogen-Induced Proliferation in Cultured Hepatocytes Involves Cyclin D1, P21CIP1 and P27KIP1 (Q62804637) (← links)
- Cyclins and breast cancer (Q79922062) (← links)